Neoadjuvant trastuzumab + FEC for HER2-positive breast cancer.

Zdroj: Inpharma Weekly. 4/30/2005, Issue 1485, p9-9. 1/4p.
Databáze: Academic Search Ultimate
Externí odkaz: